The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Osimertinib: First Global Approval
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Tan, C.-S., Gilligan, D., & Pacey, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00246-6 · Cited by 387
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
Planchard, D., Loriot, Y., André, F., Gobert, A., Auger, N., Lacroix, L., & Soria, J. C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv319 · Cited by 311
Mechanisms of Acquired Resistance to AZD9291
Kim, T. M., Song, A., Kim, D.-W., Kim, S., Ahn, Y.-O., Keam, B., Jeon, Y. K., Lee, S.-H., Chung, D. H., & Heo, D. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000688 · Cited by 222
Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155
Liao, B.-C., Lin, C., & Yang, J. C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000164 · Cited by 150
Oxnard, G. R., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Yu, H. A., Saka, H., Horn, L., Goto, K., Ohe, Y., Cantarini, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2509 · Cited by 46
Ahn, M. J., Tsai, C. M., Yang, J. C.-H., Shepherd, F. A., Satouchi, M., Kim, D. W., Bazhenova, L. A., Hirashima, T., Rukazenkov, Y., Cantarini, M., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31724-5 · Cited by 44
Cited by
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
Ayati, A., Moghimi, S., Salarinejad, S., Safavi, M., Pouramiri, B., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103811 · Cited by 379
Metadata
- Authors
- Greig, S. L.
- Venue
- Drugs
- Published
- 2016-01-04
- Volume
- 76
- Issue
- 2
- Pages
- 263-273
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2286158735
- Cited by
- 322
- References
- 18
- FWCI
- 25.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osimertinib: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-015-0533-4
- The paper
- Greig, S. L. (2016). Osimertinib: First Global Approval. Drugs. https://doi.org/10.1007/s40265-015-0533-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.